synthetic antibody targeting SARS-CoV-2 spike protein S1 (Icahn School of Medicine at Mount Sinai/GenScript)

N/A

Report date: 2025/01/26 16:24:36

Base Information

Drug Namesynthetic antibody targeting SARS-CoV-2 spike protein S1 (Icahn School of Medicine at Mount Sinai/GenScript)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMount Sinai Medical Center/Miami Jewish Home Andhospital For Theed Home Healthency
China Registration ClassN/A

Develop Information

Active CompaniesMount Sinai Medical Center/Miami Jewish Home Andhospital For Theed Home HealthencyNanjingjinsirui Science & Technology Biology Corp
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A